Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.4K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

5.7K
Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current Molecular Combination Therapies Used for the Treatment of Breast Cancer.

International journal of molecular sciences·2022
Same author

The Use of Nanomedicine to Target Signaling by the PAK Kinases for Disease Treatment.

Cells·2021
Same author

Enhanced oral bioavailability and bioefficacy of phloretin using mixed polymeric modified self-nanoemulsions.

Food science & nutrition·2020
Same author

Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma <i>In Situ</i> by Vitamin D Compounds.

Cancer prevention research (Philadelphia, Pa.)·2020
Same author

KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.

Chemical research in toxicology·2019
Same author

P21 activated kinase signaling in cancer.

Seminars in cancer biology·2018

Related Experiment Video

Updated: Jun 11, 2025

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.9K

Inhibition of NAMPT by PAK4 Inhibitors.

Yiling Wang1, Audrey Minden1

  • 1Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.

International Journal of Molecular Sciences
|September 28, 2024
PubMed
Summary

PAK4 inhibitors, including KPT-9274, not only target PAK4 but also NAMPT, impacting cancer cell growth. This dual inhibition suggests a complex mechanism of action for these cancer therapeutics.

Keywords:
NADNAMPTPAK1PAK4cancer treatmentdual inhibitors

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.9K
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.1K

Related Experiment Videos

Last Updated: Jun 11, 2025

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.9K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

5.9K
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The serine/threonine kinase PAK4 is implicated in cancer progression, with its overexpression linked to poor prognosis.
  • KPT-9274, a known PAK4 inhibitor, demonstrates anti-cancer effects in triple-negative breast cancer and other cancer types.
  • KPT-9274 also inhibits NAMPT (nicotinamide phosphoribosyltransferase), an enzyme critical for NAD synthesis and cellular energy.

Purpose of the Study:

  • To investigate whether the growth inhibitory effects of KPT-9274 are due to PAK4 inhibition, NAMPT inhibition, or both.
  • To determine if other PAK4 inhibitors also exhibit NAMPT inhibitory activity.
  • To elucidate the molecular mechanisms underlying the dual inhibition of PAK4 and NAMPT by PAK4 inhibitors.

Main Methods:

  • Testing multiple PAK4 inhibitors for their effects on cell growth and NAMPT activity.
  • Utilizing cell-free assays and a breast cancer cell line to assess NAMPT inhibition.
  • Employing molecular docking studies to identify interaction sites between PAK4 inhibitors, PAK4, and NAMPT.

Main Results:

  • Multiple PAK4 inhibitors were confirmed to also inhibit NAMPT activity.
  • Both cell-free and cellular assays demonstrated NAMPT inhibition by these compounds.
  • Molecular docking revealed specific interactions between PAK4 inhibitors and residues on both PAK4 and NAMPT.

Conclusions:

  • PAK4 inhibitors possess a more complex mechanism of action than previously recognized, involving dual inhibition of PAK4 and NAMPT.
  • The findings suggest that the anti-cancer efficacy of these inhibitors may stem from this combined inhibitory effect.
  • Further research is warranted to fully understand the implications of this dual inhibition on cancer cell growth and therapeutic strategies.